Method of treatment of attention deficit/hyperactivity disorder (ADHD)
The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
1. A method of antagonizing 5-HT7 and 5HT1B receptor activity in a patient suffering from ADHD, consisting of administering to the patient in need thereof a therapeutically effective amount of viloxazine, wherein the administration antagonizes both receptors.
2. The method of claim 1 , wherein the therapeutically effective amount is from about 20 to about 800 mg a day.
3. The method of claim 1 , wherein the therapeutically effective amount is from about 10 to about 600 mg a day.
4. The method of claim 3 , wherein the therapeutically effective amount is from about 150 to about 400 mg a day.
5. The method of claim 4 , wherein the therapeutically effective amount is from 150 to 300 mg a day.
6. The method of claim 1 , which provides an improved adverse effect profile.
7. The method of claim 1 , wherein the patient is a human child.
8. The method of claim 1 , wherein the patient further suffers from anxiety, depression, or bipolar disorder.
9. The method of claim 1 , wherein the patient further suffers from obsessive compulsive disorder, Tourette's Syndrome, or Post Traumatic Stress Disorder.